| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 20 | 2023 | 350 | 2.410 |
Why?
|
| Puerto Rico | 39 | 2024 | 1376 | 2.060 |
Why?
|
| Papillomavirus Infections | 18 | 2022 | 363 | 1.820 |
Why?
|
| Neoplasms | 17 | 2023 | 1341 | 1.810 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2022 | 36 | 0.950 |
Why?
|
| Papillomaviridae | 8 | 2015 | 136 | 0.870 |
Why?
|
| Terminal Care | 2 | 2021 | 53 | 0.840 |
Why?
|
| Papillomavirus Vaccines | 3 | 2022 | 168 | 0.820 |
Why?
|
| Early Detection of Cancer | 7 | 2023 | 428 | 0.810 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 11 | 0.790 |
Why?
|
| Registries | 5 | 2019 | 431 | 0.710 |
Why?
|
| Hospice Care | 1 | 2021 | 20 | 0.700 |
Why?
|
| Humans | 78 | 2024 | 42163 | 0.680 |
Why?
|
| Female | 64 | 2024 | 24018 | 0.670 |
Why?
|
| Vaginal Smears | 7 | 2013 | 62 | 0.630 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 130 | 0.630 |
Why?
|
| United States | 17 | 2024 | 5072 | 0.610 |
Why?
|
| Breast Neoplasms | 9 | 2022 | 1679 | 0.590 |
Why?
|
| Aged | 31 | 2024 | 7982 | 0.590 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 49 | 0.590 |
Why?
|
| Adult | 43 | 2024 | 13458 | 0.540 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 479 | 0.530 |
Why?
|
| Middle Aged | 41 | 2024 | 11819 | 0.500 |
Why?
|
| Patient Acceptance of Health Care | 7 | 2023 | 471 | 0.460 |
Why?
|
| Sunscreening Agents | 1 | 2014 | 11 | 0.440 |
Why?
|
| Health Knowledge, Attitudes, Practice | 7 | 2022 | 959 | 0.440 |
Why?
|
| Sunlight | 1 | 2014 | 48 | 0.430 |
Why?
|
| Adolescent | 19 | 2021 | 5950 | 0.430 |
Why?
|
| Young Adult | 17 | 2021 | 4936 | 0.430 |
Why?
|
| Retrospective Studies | 12 | 2024 | 2485 | 0.420 |
Why?
|
| Risk Factors | 12 | 2022 | 3942 | 0.420 |
Why?
|
| Multiple Myeloma | 2 | 2024 | 45 | 0.400 |
Why?
|
| Health Behavior | 3 | 2023 | 568 | 0.390 |
Why?
|
| Self Administration | 1 | 2013 | 67 | 0.390 |
Why?
|
| Specimen Handling | 1 | 2013 | 61 | 0.390 |
Why?
|
| Cyclonic Storms | 2 | 2024 | 75 | 0.380 |
Why?
|
| Ambulatory Care | 1 | 2013 | 81 | 0.380 |
Why?
|
| Incidence | 11 | 2024 | 1054 | 0.380 |
Why?
|
| SEER Program | 5 | 2024 | 157 | 0.370 |
Why?
|
| Environmental Exposure | 1 | 2014 | 247 | 0.370 |
Why?
|
| Genetic Testing | 1 | 2011 | 90 | 0.340 |
Why?
|
| Medicare | 3 | 2022 | 326 | 0.340 |
Why?
|
| Palliative Care | 2 | 2021 | 61 | 0.320 |
Why?
|
| Information Seeking Behavior | 1 | 2010 | 26 | 0.310 |
Why?
|
| Uterine Cervical Dysplasia | 5 | 2007 | 41 | 0.300 |
Why?
|
| Health Personnel | 2 | 2022 | 262 | 0.290 |
Why?
|
| DNA, Viral | 6 | 2015 | 323 | 0.290 |
Why?
|
| Attitude to Health | 2 | 2011 | 336 | 0.280 |
Why?
|
| Colorectal Neoplasms | 2 | 2023 | 502 | 0.270 |
Why?
|
| Endometrial Neoplasms | 4 | 2011 | 79 | 0.260 |
Why?
|
| Language | 2 | 2021 | 181 | 0.260 |
Why?
|
| Health Services Accessibility | 6 | 2021 | 680 | 0.250 |
Why?
|
| Cancer Care Facilities | 2 | 2010 | 19 | 0.250 |
Why?
|
| Communication Barriers | 1 | 2006 | 60 | 0.240 |
Why?
|
| Health Status Disparities | 3 | 2019 | 705 | 0.240 |
Why?
|
| Male | 20 | 2024 | 22779 | 0.230 |
Why?
|
| Decision Making | 2 | 2006 | 242 | 0.220 |
Why?
|
| Genital Neoplasms, Female | 1 | 2024 | 17 | 0.220 |
Why?
|
| Patient Education as Topic | 2 | 2019 | 234 | 0.210 |
Why?
|
| Mass Screening | 4 | 2012 | 531 | 0.210 |
Why?
|
| Aged, 80 and over | 10 | 2019 | 2803 | 0.210 |
Why?
|
| Benzodiazepines | 1 | 2023 | 19 | 0.210 |
Why?
|
| Caribbean Region | 5 | 2023 | 75 | 0.210 |
Why?
|
| Hospital Mortality | 1 | 2005 | 206 | 0.210 |
Why?
|
| Socioeconomic Factors | 4 | 2006 | 1221 | 0.200 |
Why?
|
| Texas | 9 | 2010 | 428 | 0.200 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2023 | 2 | 0.200 |
Why?
|
| Occult Blood | 1 | 2023 | 32 | 0.200 |
Why?
|
| Paraproteinemias | 1 | 2023 | 4 | 0.200 |
Why?
|
| Cytogenetics | 1 | 2022 | 3 | 0.200 |
Why?
|
| Civil Defense | 1 | 2023 | 16 | 0.190 |
Why?
|
| Sexual Behavior | 4 | 2011 | 634 | 0.190 |
Why?
|
| Cervix Uteri | 2 | 2013 | 47 | 0.190 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2022 | 18 | 0.190 |
Why?
|
| Genetic Markers | 1 | 2022 | 146 | 0.190 |
Why?
|
| Prognosis | 3 | 2022 | 850 | 0.190 |
Why?
|
| Sex Factors | 4 | 2014 | 1008 | 0.180 |
Why?
|
| Quality of Life | 3 | 2021 | 599 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 1 | 2022 | 225 | 0.170 |
Why?
|
| Agriculture | 3 | 2005 | 65 | 0.170 |
Why?
|
| Recombinant Proteins | 1 | 2022 | 522 | 0.170 |
Why?
|
| Population Surveillance | 2 | 2019 | 245 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 209 | 0.170 |
Why?
|
| Vaccination | 1 | 2022 | 332 | 0.170 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 573 | 0.160 |
Why?
|
| Prevalence | 3 | 2018 | 1597 | 0.160 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 175 | 0.150 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 107 | 0.150 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 268 | 0.150 |
Why?
|
| Uterine Neoplasms | 1 | 2019 | 51 | 0.150 |
Why?
|
| Capacity Building | 1 | 2019 | 99 | 0.150 |
Why?
|
| Social Class | 5 | 2011 | 286 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 53 | 0.140 |
Why?
|
| Mammography | 4 | 2009 | 211 | 0.130 |
Why?
|
| Survival Rate | 5 | 2021 | 353 | 0.130 |
Why?
|
| Health Services Misuse | 1 | 2017 | 20 | 0.130 |
Why?
|
| Case-Control Studies | 9 | 2006 | 1266 | 0.130 |
Why?
|
| Oncogene Proteins, Viral | 3 | 2005 | 25 | 0.130 |
Why?
|
| Logistic Models | 7 | 2015 | 1001 | 0.130 |
Why?
|
| Age Factors | 4 | 2014 | 1139 | 0.130 |
Why?
|
| Insulin Resistance | 2 | 2011 | 199 | 0.130 |
Why?
|
| Uterine Cervical Diseases | 2 | 2013 | 14 | 0.120 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 223 | 0.120 |
Why?
|
| Poverty | 2 | 2009 | 395 | 0.120 |
Why?
|
| Public Health | 1 | 2019 | 405 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2005 | 150 | 0.110 |
Why?
|
| Mexican Americans | 2 | 2009 | 224 | 0.110 |
Why?
|
| Protective Clothing | 1 | 2014 | 6 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2019 | 467 | 0.110 |
Why?
|
| Repressor Proteins | 3 | 2005 | 267 | 0.110 |
Why?
|
| Unsafe Sex | 2 | 2012 | 162 | 0.110 |
Why?
|
| Multivariate Analysis | 4 | 2015 | 638 | 0.110 |
Why?
|
| Ovarian Neoplasms | 3 | 2002 | 406 | 0.100 |
Why?
|
| Anus Diseases | 1 | 2013 | 17 | 0.100 |
Why?
|
| Anal Canal | 1 | 2012 | 32 | 0.100 |
Why?
|
| Health Surveys | 1 | 2014 | 401 | 0.100 |
Why?
|
| Cultural Characteristics | 3 | 2011 | 128 | 0.100 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 225 | 0.090 |
Why?
|
| Latin America | 2 | 2023 | 53 | 0.090 |
Why?
|
| Survival Analysis | 3 | 2014 | 362 | 0.090 |
Why?
|
| Biotechnology | 1 | 2011 | 15 | 0.090 |
Why?
|
| Insurance, Health | 3 | 2022 | 143 | 0.090 |
Why?
|
| Consumer Health Information | 1 | 2011 | 24 | 0.090 |
Why?
|
| Marketing | 1 | 2011 | 44 | 0.090 |
Why?
|
| Health Promotion | 2 | 2009 | 691 | 0.090 |
Why?
|
| Self Care | 1 | 2012 | 173 | 0.090 |
Why?
|
| User-Computer Interface | 1 | 2011 | 74 | 0.090 |
Why?
|
| Comprehensive Health Care | 1 | 2010 | 11 | 0.090 |
Why?
|
| Neoplasm Staging | 5 | 2018 | 366 | 0.080 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2010 | 10 | 0.080 |
Why?
|
| Genotype | 1 | 2013 | 796 | 0.080 |
Why?
|
| Self Efficacy | 2 | 2009 | 211 | 0.080 |
Why?
|
| Evidence-Based Practice | 1 | 2010 | 48 | 0.080 |
Why?
|
| Human papillomavirus 16 | 2 | 2007 | 37 | 0.080 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 245 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2010 | 187 | 0.070 |
Why?
|
| Genital Neoplasms, Male | 1 | 2008 | 2 | 0.070 |
Why?
|
| Genital Diseases, Male | 1 | 2008 | 2 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2024 | 512 | 0.070 |
Why?
|
| Condylomata Acuminata | 1 | 2008 | 6 | 0.070 |
Why?
|
| Women's Health | 2 | 2006 | 158 | 0.070 |
Why?
|
| Educational Status | 1 | 2010 | 335 | 0.070 |
Why?
|
| Trust | 1 | 2010 | 157 | 0.070 |
Why?
|
| Internet | 1 | 2010 | 234 | 0.070 |
Why?
|
| Health Education | 1 | 2011 | 358 | 0.070 |
Why?
|
| Program Development | 1 | 2009 | 237 | 0.070 |
Why?
|
| Ploidies | 1 | 2007 | 7 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2004 | 27 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2007 | 1265 | 0.070 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 61 | 0.070 |
Why?
|
| Qualitative Research | 1 | 2010 | 526 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2024 | 1729 | 0.060 |
Why?
|
| Carcinoma | 1 | 2007 | 106 | 0.060 |
Why?
|
| Cross-Sectional Studies | 5 | 2015 | 3077 | 0.060 |
Why?
|
| Chromatin | 1 | 2007 | 179 | 0.060 |
Why?
|
| Adiponectin | 1 | 2006 | 59 | 0.060 |
Why?
|
| Air Pollutants, Occupational | 1 | 2005 | 10 | 0.060 |
Why?
|
| Patient Participation | 1 | 2006 | 87 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2006 | 163 | 0.060 |
Why?
|
| Survivors | 1 | 2006 | 152 | 0.060 |
Why?
|
| Wood | 1 | 2005 | 16 | 0.060 |
Why?
|
| Physician-Patient Relations | 1 | 2006 | 146 | 0.060 |
Why?
|
| Transients and Migrants | 1 | 2005 | 42 | 0.060 |
Why?
|
| DNA-Binding Proteins | 2 | 2005 | 557 | 0.060 |
Why?
|
| Women | 1 | 2005 | 28 | 0.060 |
Why?
|
| Dust | 1 | 2005 | 55 | 0.060 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2004 | 25 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2004 | 7 | 0.050 |
Why?
|
| Vulvar Neoplasms | 1 | 2004 | 10 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2005 | 158 | 0.050 |
Why?
|
| Odds Ratio | 4 | 2010 | 587 | 0.050 |
Why?
|
| Acculturation | 1 | 2005 | 203 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2004 | 73 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2005 | 574 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2005 | 301 | 0.050 |
Why?
|
| Risk Assessment | 4 | 2010 | 845 | 0.050 |
Why?
|
| Pilot Projects | 3 | 2012 | 733 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2005 | 295 | 0.050 |
Why?
|
| Guam | 1 | 2023 | 83 | 0.050 |
Why?
|
| Efficiency | 1 | 2003 | 14 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2003 | 81 | 0.050 |
Why?
|
| Research Design | 1 | 2005 | 370 | 0.050 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2002 | 3 | 0.050 |
Why?
|
| Gynecology | 1 | 2003 | 33 | 0.050 |
Why?
|
| Peritoneal Neoplasms | 1 | 2002 | 18 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2023 | 77 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2003 | 83 | 0.050 |
Why?
|
| Menopause | 1 | 2003 | 63 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2003 | 61 | 0.050 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2002 | 44 | 0.050 |
Why?
|
| Adenofibroma | 1 | 2002 | 1 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 116 | 0.050 |
Why?
|
| Thyroid Diseases | 1 | 2002 | 6 | 0.050 |
Why?
|
| Confidence Intervals | 3 | 2010 | 162 | 0.050 |
Why?
|
| Mentors | 1 | 2003 | 143 | 0.040 |
Why?
|
| Endometriosis | 1 | 2002 | 81 | 0.040 |
Why?
|
| Disease Progression | 1 | 2023 | 661 | 0.040 |
Why?
|
| Emotions | 1 | 2023 | 251 | 0.040 |
Why?
|
| Data Collection | 2 | 2015 | 210 | 0.040 |
Why?
|
| Pamphlets | 1 | 2019 | 27 | 0.040 |
Why?
|
| International Cooperation | 1 | 2019 | 51 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2006 | 456 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 541 | 0.040 |
Why?
|
| Medical Tourism | 1 | 2019 | 4 | 0.040 |
Why?
|
| International Agencies | 1 | 2019 | 6 | 0.040 |
Why?
|
| Sex Distribution | 2 | 2010 | 224 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2019 | 46 | 0.040 |
Why?
|
| Developing Countries | 1 | 2019 | 112 | 0.040 |
Why?
|
| Cause of Death | 1 | 2019 | 183 | 0.040 |
Why?
|
| Tumor Virus Infections | 2 | 2010 | 22 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 23 | 0.030 |
Why?
|
| Mastectomy, Segmental | 1 | 2017 | 25 | 0.030 |
Why?
|
| Age Distribution | 2 | 2010 | 249 | 0.030 |
Why?
|
| Hospitalization | 1 | 2021 | 482 | 0.030 |
Why?
|
| Diet | 1 | 2003 | 810 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 309 | 0.030 |
Why?
|
| Interviews as Topic | 2 | 2009 | 428 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 336 | 0.030 |
Why?
|
| California | 2 | 2009 | 531 | 0.030 |
Why?
|
| Papillomavirus E7 Proteins | 2 | 2005 | 16 | 0.030 |
Why?
|
| Pregnancy | 2 | 2011 | 1737 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2007 | 438 | 0.030 |
Why?
|
| Insurance Coverage | 2 | 2005 | 108 | 0.030 |
Why?
|
| Body Mass Index | 2 | 2011 | 916 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 238 | 0.030 |
Why?
|
| Aging | 1 | 2019 | 764 | 0.030 |
Why?
|
| Sentinel Surveillance | 1 | 2014 | 24 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2015 | 263 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2014 | 95 | 0.030 |
Why?
|
| Mexico | 2 | 2005 | 286 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2012 | 65 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2015 | 456 | 0.020 |
Why?
|
| Child | 2 | 2011 | 3381 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 725 | 0.020 |
Why?
|
| Coitus | 1 | 2011 | 12 | 0.020 |
Why?
|
| Multimedia | 1 | 2011 | 18 | 0.020 |
Why?
|
| Pregnancy in Adolescence | 1 | 2011 | 34 | 0.020 |
Why?
|
| Parity | 1 | 2011 | 60 | 0.020 |
Why?
|
| Oklahoma | 1 | 2010 | 28 | 0.020 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2010 | 17 | 0.020 |
Why?
|
| Alaska | 1 | 2010 | 61 | 0.020 |
Why?
|
| Community Health Planning | 1 | 2010 | 38 | 0.020 |
Why?
|
| Micronesia | 1 | 2010 | 87 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2010 | 37 | 0.020 |
Why?
|
| Population Groups | 1 | 2010 | 59 | 0.020 |
Why?
|
| Reference Values | 1 | 2010 | 207 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 358 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2010 | 81 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 487 | 0.020 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2011 | 172 | 0.020 |
Why?
|
| Schools | 1 | 2011 | 283 | 0.020 |
Why?
|
| Curriculum | 1 | 2011 | 311 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 2008 | 36 | 0.020 |
Why?
|
| Sexual Partners | 1 | 2011 | 325 | 0.020 |
Why?
|
| Indians, North American | 1 | 2010 | 179 | 0.020 |
Why?
|
| Anus Neoplasms | 1 | 2008 | 43 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2009 | 190 | 0.020 |
Why?
|
| Image Cytometry | 1 | 2007 | 6 | 0.020 |
Why?
|
| Human papillomavirus 18 | 1 | 2007 | 6 | 0.020 |
Why?
|
| Virus Integration | 1 | 2007 | 65 | 0.020 |
Why?
|
| Biopsy | 1 | 2007 | 176 | 0.020 |
Why?
|
| Psychometrics | 1 | 2009 | 350 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2011 | 1574 | 0.020 |
Why?
|
| Hela Cells | 1 | 2007 | 370 | 0.020 |
Why?
|
| Outpatients | 1 | 2006 | 34 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 454 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2006 | 64 | 0.020 |
Why?
|
| Time Factors | 1 | 2010 | 1848 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 649 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2007 | 317 | 0.020 |
Why?
|
| New Mexico | 1 | 2005 | 36 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2005 | 34 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2006 | 89 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 2005 | 63 | 0.010 |
Why?
|
| Infant | 1 | 2009 | 1143 | 0.010 |
Why?
|
| Endometrium | 1 | 2006 | 60 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 2005 | 10 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2005 | 73 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2005 | 57 | 0.010 |
Why?
|
| Breast Self-Examination | 1 | 2005 | 13 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 532 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 2005 | 62 | 0.010 |
Why?
|
| Physical Examination | 1 | 2005 | 45 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2006 | 225 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2005 | 152 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2009 | 1516 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 253 | 0.010 |
Why?
|
| Rosaniline Dyes | 1 | 2004 | 4 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2004 | 26 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 200 | 0.010 |
Why?
|
| Contraceptives, Oral | 1 | 2003 | 17 | 0.010 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2003 | 9 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 997 | 0.010 |
Why?
|
| Social Support | 1 | 2006 | 438 | 0.010 |
Why?
|
| Fellowships and Scholarships | 1 | 2003 | 32 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 1188 | 0.010 |
Why?
|
| Dietary Fiber | 1 | 2003 | 50 | 0.010 |
Why?
|
| Risk | 1 | 2003 | 289 | 0.010 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2002 | 20 | 0.010 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2002 | 19 | 0.010 |
Why?
|
| Vitamin E | 1 | 2003 | 56 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2002 | 14 | 0.010 |
Why?
|
| Diet Surveys | 1 | 2003 | 97 | 0.010 |
Why?
|
| Obesity | 1 | 2011 | 1131 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 1559 | 0.010 |
Why?
|
| Carotenoids | 1 | 2003 | 74 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 602 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2003 | 403 | 0.010 |
Why?
|
| Rural Population | 1 | 2005 | 352 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2002 | 174 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2003 | 658 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2003 | 233 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2002 | 1051 | 0.010 |
Why?
|
| Hypertension | 1 | 2006 | 823 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2003 | 461 | 0.010 |
Why?
|
| Smoking | 1 | 2005 | 1019 | 0.010 |
Why?
|
| HIV Infections | 1 | 2011 | 2535 | 0.010 |
Why?
|
| Mice | 1 | 2003 | 6490 | 0.010 |
Why?
|
| Animals | 1 | 2003 | 16695 | 0.000 |
Why?
|